{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:30:24Z","timestamp":1764052224305,"version":"3.45.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010814","name":"Anhui Provincial Department of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical application of histamine H2 receptor antagonists (H2 RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV), focusing on the rationality of H2 RAs use, the utilization rates and costs of different H2 RAs agents, to provide a reference for the rational use of H2 RAs in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Evaluation criteria for the rational use of H2 RAs in CINV prevention were established based on domestic and international drug package inserts, clinical guidelines, and national expert consensus. A retrospective study was conducted, and the rationality of H2 RA use in CINV prevention was analyzed and evaluated using the Attribute Hierarchy Model (AHM) method among 323 patients discharged from the People\u2019s Hospital of Bozhou in April 2024. The clinical application of different H2 RAs was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The significant issues of irrational use of H2 RAs in CINV prevention included inappropriate solvent and incompatibility (71.83%), use without indications (70.59%), inappropriate dosage and administration (45.82%), prolonged duration of therapy (30.65%), lack of laboratory monitoring (24.46%), and unreasonable efficacy evaluation (23.84%). The mean case score was 71.03 \u00b1 11.06, with oncology cases scoring 70.16 \u00b1 11.03 and non-oncology cases scoring 74.81 \u00b1 10.44, indicating a statistically significant difference (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). The mean cost of H2 RAs in CINV prevention was 114.46 \u00b1 132.64 yuan, accounting for 2.72% of the mean total drug expenditure. Specifically, the average price of H2 RAs was 123.09 \u00b1 139.45 yuan in oncology cases and 70.89 \u00b1 84.64 yuan in non-oncology cases, also with a statistically significant difference (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). The clinical application of H2 RAs showed a preference for the higher-priced ranitidine (88.54%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>H2 RAs remain widely used in the prevention of CINV; however, the majority of cases (98.45%) demonstrated irrational use, particularly prophylactic administration without appropriate indications. The rationality of H2 RAs use in oncology departments was lower than that in non-oncology departments, while the associated drug costs were higher. Strengthened management of H2 RAs application in CINV prevention is needed to improve the rationality of drug use and to ensure safety, efficacy, and cost-effectiveness for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1700075","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:26:38Z","timestamp":1764051998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the clinical application of histamine H2 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting based on the attribute hierarchy model method"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiawei","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingbing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/236385a0","article-title":"Definition and antagonism of histamine H2-receptors","volume":"236","author":"Black","year":"1972","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.14009\/j.issn.1672-2124.2024.06.018","article-title":"Rationality evaluation of clinical use of Acanthopanax senticosus injection based on analytic hierarchy model","volume":"24","author":"Cheng","year":"2024","journal-title":"Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi"},{"key":"B3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3760\/cma.j.cn112152-20240123-00046","article-title":"Chinese guidelines for the prevention and treatment of nausea and vomiting related to antitumor therapy (2023 edition)","volume":"46","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3760\/cma.j.cn112137-20220810-01724","article-title":"Chinese expert consensus on the prevention and treatment of nausea and vomiting related to cancer drug therapy (2022 edition)","volume":"102","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B5","first-page":"442","article-title":"Chinese expert consensus on the prevention and treatment of delayed nausea and vomiting (2022 edition)","volume":"28","year":"2023","journal-title":"Linchuang Zhongliuxue Zazhi"},{"key":"B6","first-page":"140","volume-title":"Chinese national formulary (chemical drugs and biologics, pediatric edition)","year":"2013"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/00002018-200124010-00004","article-title":"Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists","volume":"24","author":"Fisher","year":"2001","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.13286\/j.1001-5213.2022.04.17","article-title":"Evaluation of rational prophylactic use of antibiotics in neurosurgery based on analytic hierarchy model","volume":"42","author":"Meng","year":"2022","journal-title":"Zhongguo Yiyuan Yaoxue Zazhi"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.2147","article-title":"Effectiveness and safety of histamine H2 receptor antagonists: an umbrella review of meta-analyses","volume":"63","author":"Meng","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"B10","unstructured":"NCCN clinical practice guidelines in oncology: antiemesis 2024, version 1 [EB\/OL]\n          \n          \n          2023"},{"key":"B11","first-page":"1","article-title":"Guiding principles for clinical application of proton pump inhibitors (2020 edition)","volume":"28","year":"2021","journal-title":"Zhongguo Shiyong Xiangcun Yisheng Zazhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.13493\/j.issn.1672-7878.2016.05-047","article-title":"Analysis of one case of severe anaphylactic shock induced by intravenous infusion of cimetidine","volume":"13","author":"Peng","year":"2016","journal-title":"Kanggan Yaoxue"},{"key":"B13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.19401\/j.cnki.1007-3639.2018.12.011","article-title":"Shanghai expert consensus on the whole-process management of chemotherapy-induced nausea and vomiting (2018 edition)","volume":"28","year":"2018","journal-title":"Zhongguo Aizheng Zazhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.19401\/j.cnki.1007-3639.2024.01.008","article-title":"Shanghai expert consensus on the whole-process management of nausea and vomiting induced by antitumor therapy (2024 edition)","volume":"34","year":"2024","journal-title":"Zhongguo Aizheng Zazhi"},{"key":"B15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.19577\/j.1007-4406.2022.07.009","article-title":"Application of analytic hierarchy model in the evaluation of palonosetron drug utilization","volume":"31","author":"Song","year":"2022","journal-title":"Zhongguo Linchuang Yaoxue Zazhi"},{"key":"B16","unstructured":"IRESSA (gefitinib tablets) label [EB\/OL]\n          \n          \n          2005"},{"key":"B17","unstructured":"SPRYCEL (dasatinib) label [EB\/OL]\n          \n          \n          2006"},{"key":"B18","unstructured":"ZANTAC (ranitidine hydrochloride) label [EB\/OL]\n          \n          \n          2009"},{"key":"B19","unstructured":"PEPCID (famotidine) label [EB\/OL]\n          \n          \n          2018"},{"key":"B20","unstructured":"NERLYNX (neratinib) label [EB\/OL]\n          \n          \n          2021"},{"key":"B21","unstructured":"RETEVMO (selpercatinib) label [EB\/OL]\n          \n          \n          2024"},{"key":"B22","first-page":"98","article-title":"Application of analytic hierarchy model (AHM) in quality evaluation","author":"Wang","year":"2006","journal-title":"Shuxue Shijian Yu Renshi"},{"key":"B23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.14109\/j.cnki.xyylc.2024.01.13","article-title":"Rationality evaluation of tanreqing injection based on analytic hierarchy model","volume":"43","author":"Yang","year":"2024","journal-title":"Zhongguo Xinyao Yu Linchuang Zazhi"},{"key":"B24","first-page":"263","article-title":"Guideline for the prevention and treatment of tumor therapy-related vomiting (2014 edition)","volume":"19","author":"Yu","year":"2014","journal-title":"Linchuang Zhongliuxue Zazhi"},{"key":"B25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.13286\/j.1001-5213.2022.05.01","article-title":"Guideline for the pharmacological prevention and treatment of chemotherapy-induced nausea and vomiting","volume":"42","author":"Zhang","year":"2022","journal-title":"Zhongguo Yiyuan Yaoxue Zazhi"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.16073\/j.cnki.cjcpt.2004.11.034","article-title":"Clinical study of H2 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting","volume":"11","author":"Zheng","year":"","journal-title":"Zhongliu Fangzhi Zazhi"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.13820\/j.cnki.gdyx.2004.09.063","article-title":"Comparison of clinical application of proton pump inhibitors and H2 receptor antagonists in chemotherapy","author":"Zheng","year":"","journal-title":"Guangdong Yixue"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:26:49Z","timestamp":1764052009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1700075"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1700075","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"article-number":"1700075"}}